BLACKSBURG, VA — September 3, 2019 — Landos Biopharma,Inc.,today announced that Dr. Josep Bassaganya-Riera, Chairman, President and Chief Executive Officer, will present at the following conferences in New York:

Event: BioCentury 26th Annual NewsMakers in the Biotech Industry

Sept. 6, 2019 Location: Millennium Times Square

Date/Time: Friday, Sept. 6, at 9:20 a.m. EDT

Event: H.C. Wainwright 21st Annual Global Investment Conference, Sept. 8-10, 2019

Location: Lotte New York Palace Hotel

Date/Time: Tuesday, Sept. 10, at 3:50 p.m. EDT

Webcast: A live and archived webcast of the presentation will be available at

About Landos Biopharma

Landos Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of first-in-class oral therapeutics for patients with autoimmune diseases. Landos’ lead clinical asset, BT-11, is a first-in-class, oral therapeutic that acts locally in the gastrointestinal tract for treatment of inflammatory bowel disease (IBD). The company has completed Phase 1 clinical testing and has initiated Phase 2 clinical testing of BT-11 for inflammatory bowel disease in 2019. Landos also has a robust pipeline of new compounds for other autoimmune diseases, several of which Landos anticipates will advance to IND and Phase 1 clinical testing in 2020. Landos is headquartered in Blacksburg, Va. For more information, please visit or contact or follow us @Landosbio.


Chiara Russo (investors)

Solebury Trout


Rich Allan (media)

Solebury Trout